Clinical Trial Update: Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating TQB2928 in combination with a third-generation EGFR tyrosine kinase inhibitor for advanced non-small cell lung cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TQB2928
• Third-generation EGFR Tyrosine Kinase Inhibitor

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Advanced Non-small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING